Ankur Dhingra

Ankur Dhingra, listed as finance chief, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Summit Therapeutics Inc., Illumina, Inc. and CareDx, Inc. Over a trading history stretching from 24 November 2021 to 5 March 2026, the count stands at 12 filings.

Every open-market trade on record is a purchase: 7 purchases worth €1.2M, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 5 share grants.

Half of the purchases are above €188k and half below. 5 out of 7 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 9 March 2026 came the latest disclosure, a share grant for €1.0M in Illumina, Inc. The last purchase on record was published on 14 May 2025, which is 522 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.